U.S. ANI Pharmaceuticals, Deere & Co, Zoetis
Oct 11 (Reuters) -Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ANI Pharmaceuticals, Deere & Co and Zoetis on Friday.
HIGHLIGHTS
* ANI Pharmaceuticals Inc ANIP.O: Piper Sandler initiates coverage with overweight rating |
* Deere & Co DE.N: JP Morgan raises target price to $420 from $360 |
* Zoetis Inc ZTS.N: JP Morgan raises target price to $230 from $22 |
Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical order.
* Advanced Micro Devices AMD.O: Piper Sandler raises target price to $200 from $175 |
* ANI Pharmaceuticals Inc ANIP.O: Piper Sandler initiates coverage with overweight rating |
* ANI Pharmaceuticals Inc ANIP.O: Piper Sandler initiates coverage with price target $68 |
* Arhaus Inc ARHS.O: Wedbush initiates coverage with neutral rating; price target $11 |
* Celanese Corp CE.N: RBC cuts target price to $163 from $167 |
* Chemours CC.N: RBC cuts target price to $28 from $35 |
* Deere & Co DE.N: JP Morgan raises target price to $420 from $360 |
* Delta Air Lines Inc DAL.N: JP Morgan raises target price to $80 from $68 |
* Domino's Pizza Inc DPZ.N: JP Morgan cuts target price to $450 from $470 |
* Domino's Pizza Inc DPZ.N: Piper Sandler cuts target price to $422 from $429 |
* Domino's Pizza Inc DPZ.N: RBC cuts target price to $490 from $500 |
* Domino's Pizza Inc DPZ.N: Stifel cuts target price to $470 from $480 |
* Duckhorn Portfolio Inc NAPA.N: RBC cuts to sector perform from outperform |
* Duckhorn Portfolio Inc NAPA.N: RBC raises target price to $11.1 from $11 |
* Eastman Chemical Co EMN.N: RBC raises target price to $107 from $100 |
* Edgewise Therapeutics Inc EWTX.O: Piper Sandler raises target price to $51 from $48 |
* Flutter Entertainment Plc FLUT.N: HSBC raises target price to $223 from $209 |
* Huntsman Corp HUN.N: RBC raises target price to $24 from $21 |
* Idexx Laboratories Inc IDXX.O: JP Morgan cuts target price to $575 from $630 |
* Intuitive Surgical Inc ISRG.O: JP Morgan raises target price to $575 from $495 |
* Westlake Corp WLK.N: RBC cuts target price to $170 from $174 |
* Xencor Inc XNCR.O: Wedbush raises target price to $38 from $34 |
* Zoetis Inc ZTS.N: JP Morgan raises target price to $230 from $225 |
(Compiled by Bengaluru Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
